Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462006 · ClinicalTrials.gov registry record · NA
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01462006 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 32 participants.
The verdict
NCT01462006, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Idiopathic pulmonary fibrosis (IPF) is an illness characterized by progressive decline in lung function and premature death from respiratory failure. Fibrocytes are a novel population of bone marrow-derived circulating progenitor cells that have been shown to traffic to the lungs and contribute to fibrosis in animal models of pulmonary fibrosis, and whose numbers correlate with the degree of fibrosis and with survival in human pulmonary fibrosis. The investigators propose to test the hypothesis that therapy with the mTOR inhibitor, sirolimus, reduces the number of circulating fibrocytes in patients with IPF. The investigators propose to test this hypothesis in short-term pilot trial of sirolimus in patients with IPF to determine its effect on the number and phenotype of circulating fibrocytes.
Interventions
- OTHER Placebo
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462006
The ClinicalTrials.gov registry entry for NCT01462006 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01462006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462006 about?
NCT01462006 is a clinical study titled "Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)". Idiopathic pulmonary fibrosis (IPF) is an illness characterized by progressive decline in lung function and premature death from respiratory failure. Fibrocytes are a novel population of bone marrow-derived circulating progenitor cells that have been shown to traffic to the lungs and contribute to f...
What is the current status of trial NCT01462006?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2011-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01462006?
The interventions under investigation include: Placebo (OTHER), sirolimus (DRUG).
Who is sponsoring clinical trial NCT01462006?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.